20200402PR-EN availability URD 2019
Category: dates
Availability of Preparatory Documents for the Combined General Meeting of May 27, 2020
20200403 – availability doc AG – EN
Major R&D milestones achieved in 2019 and strong clinical activity in 2020
20200311 Resultats 2019 EN
BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti- CTLA4 antibody and GM-CSF to target the tumor microenvironment
Poster BT-001Marchand, Semmrich, Fend et al.Immuno-Oncology summitDownload the poster herePoster Presentation
Transgene and BioInvent to Present Data on BT-001, an Oncolytic Virus Encoding for an Anti-CTLA4 Antibody, at Upcoming Congresses
20200303 BT-001 presentations EN
First Patient Dosed with Transgene’s Oncolytic Virus TG6002, Administered by Intrahepatic Artery Infusion in Colorectal Cancer with Liver Metastases
20200220 PR FPI 6002.03 EN
Transgene and NEC Start Two Clinical Trials with TG4050, an individualized AI-Powered Cancer Vaccine for Ovarian and Head & Neck Cancers
20200107 PR TG4050 FPI – EN
Transgene Announces Financial Calendar for 2020
20191218 Financial calendar 2020 EN
Transgene Reports on the Combination Trial of TG4010, Chemotherapy and Nivolumab in Non-Small Cell Lung Cancer
20191212 PR TG4010_EN_results
Transgene and BioInvent announce compelling preclinical data for BT-001 in solid tumors
20191211 PR preclinical BT001 EN